The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
 
Sinead Toomey
No Relationships to Disclose
 
Alex J Eustace
No Relationships to Disclose
 
Joanna Fay
No Relationships to Disclose
 
Malgorzata Milewska
Research Funding - Bayer (Inst)
 
Ausra Teiserkiene
No Relationships to Disclose
 
Elaine Kay
Consulting or Advisory Role - Almac Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Dublin City University (Inst); RCSI (Inst)
 
Darran O'Connor
Consulting or Advisory Role - Pfizer
 
Leonie S Young
No Relationships to Disclose
 
Norma O'Donovan
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); GlaxoSmithKline (Inst)
 
William Grogan
No Relationships to Disclose
 
Oscar S. Breathnach
No Relationships to Disclose
 
Janice Maria Walshe
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
M. John Kennedy
No Relationships to Disclose
 
Arnold D. Hill
No Relationships to Disclose
 
Colm Power
No Relationships to Disclose
 
Deirdre Duke
No Relationships to Disclose
 
Niamh Hambly
No Relationships to Disclose
 
William M. Gallagher
Employment - OncoMark
Leadership - OncoMark
Stock and Other Ownership Interests - OncoMark
Patents, Royalties, Other Intellectual Property - OncoMark
 
John Crown
Honoraria - Bayer; Eisai; Genomic Health; New Oncology; Novartis; Pfizer; Teva
Consulting or Advisory Role - Bayer; Eisai; Genomic Health; New Oncology; Novartis; Pfizer; Teva
Speakers' Bureau - Genomic Health; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Roche (Inst)
 
Bryan Hennessy
No Relationships to Disclose